Pf Magazine

Welcome to your go-to source for the newest updates, insights, events, job openings, and advancements in the pharmaceutical sector. Our platform provides you with the tools to stay informed on your schedule. Whether it's through print, online, or social media, we deliver the essential information you need to advance your career.

International

English

Magazine, Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#3452861

United Kingdom

#503342

Health/Biotechnology and Pharmaceuticals

#325

Traffic sources

Monthly visitors

Articles

New drug discovery platform accelerates genetic illness treatments - Pf Media

3 weeks ago | pf-media.co.uk | Emma Cooper

bioXcelerate has unveiled a new platform designed to rapidly accelerate drug discovery, solving critical challenges in genetic analysis and drug development. With a 99% accuracy rate, the technology will help researchers pinpoint disease-associated risk genes 98% faster than traditional industry methods. This means processes the used to take days, now take minutes, driving faster breakthroughs in genetic research.
Next-generation breast cancer drug targets tumours before they have a chance to grow

3 weeks ago | pf-media.co.uk | Emma Cooper

A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy.
More patients set to become eligible for AstraZeneca’s Forxiga

3 weeks ago | pf-media.co.uk | Emma Cooper

Following the review of additional clinical data, the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga (dapagliflozin) as a treatment option for Chronic Kidney Disease (CKD), for an expanded patient population.
Sapio Sciences appoints Gordon McCall as Chief Operating Officer

1 month ago | pf-media.co.uk | Emma Cooper

Sapio Sciences, the science-aware™ lab informatics platform, has announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.
NICE recommends daily pill to treat rare chronic kidney disease

1 month ago | pf-media.co.uk | Emma Cooper

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for chronic kidney disease, for use in the NHS. Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary immunoglobulin A nephropathy (IgAN), also known as Berger’s disease.
Gilead and Kite to present key data on breast, blood, and brain cancers at 2025 ASCO and EHA

1 month ago | pf-media.co.uk | Hannah McGregor

Gilead Sciences, Inc. will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, 30 May-3 June, and the 2025 European Hematology Association (EHA) Annual Congress, 12-15 June.
Final patient cohort dosed in HER-096 Phase 1b clinical trial for Parkinson’s disease

1 month ago | pf-media.co.uk | Hannah McGregor

Herantis Pharma Plc (“Herantis”), a company developing disease-modifying therapies for Parkinson’s disease, has announced the first patients have been dosed in the final cohort of its Phase 1b clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Parkinson’s disease is a devastating neurological condition affecting around 10 million people worldwide, for which there is currently no cure.
NICE, NHS England and BioMarin agree deal for continued access to rare inherited disease treatment

1 month ago | pf-media.co.uk | Hannah McGregor

NICE are consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (CLN2), a type of Batten disease. NICE draft guidance does not, at present, recommend the treatment’s use for future patients with this rare, life limiting disease due to its high price and the limited evidence of long-term effectiveness.
SMC approves Johnson & Johnson's bladder cancer therapy

1 month ago | pf-media.co.uk | Emma Cooper

Johnson & Johnson has announced that BALVERSA®▼ (erdafitinib) has been accepted for use within NHS Scotland for the treatment of eligible adults with unresectable or metastatic urothelial cancer (UC) which is harbouring susceptible fibroblast growth factor receptor (FGFR3) genetic alterations, and who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
eXmoor Pharma and KU Leuven partner to accelerate cell and gene therapy innovation

1 month ago | pf-media.co.uk | Emma Cooper

eXmoor Pharma, the integrated cell and gene therapy CDMO, has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic institutions, to support a new cell and gene therapy hub. The collaboration brings together complementary scientific, regulatory and manufacturing capabilities to accelerate innovative cell and gene therapies from bench to first-in-human trials.